Status:
UNKNOWN
Exploring the Role of Neuroactive Steroids in Tourette Syndrome
Lead Sponsor:
University of Utah
Collaborating Sponsors:
University of Miami
Albert Einstein College of Medicine
Conditions:
Tourette Syndrome in Children
Eligibility:
All Genders
8-12 years
Phase:
NA
Brief Summary
Tourette syndrome (TS) is a disabling neurodevelopmental disorder characterized by motor and phonic tics. The studies proposed in this application will explore the endocrine mechanisms underlying two ...
Detailed Description
Tourette syndrome (TS) is a disabling neurodevelopmental disorder characterized by motor and phonic tics. Available treatment strategies remain unsatisfactory, due to limited knowledge of the biologic...
Eligibility Criteria
Inclusion
- Diagnostic criteria of TS for cases (and lack of any tic disorders for controls)
- Age between 8 and 12 years old (this age range is to ensure that TS participants can perform the tic suppression task)
- confirmation of sexual development by parent and/or self-reported Tanner stage of pubic hair development.
Exclusion
- major psychiatric disorders such as a psychotic disorder, autism spectrum disorder, conduct disorder, and substance use disorder;
- other neurological disorders;
- clinically significant endocrinological disorders;
- use of therapies that can modify hormonal profile;
- pharmacotherapies that may change stress sensitivity, such as antidepressants and anxiolytics.
Key Trial Info
Start Date :
April 1 2022
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 31 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT05281445
Start Date
April 1 2022
End Date
March 31 2024
Last Update
March 16 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Utah
Salt Lake City, Utah, United States, 84112